Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)

PURPOSE: NIS HELENA documented outcomes in clinical routine practice of first-line therapy with P plus T and docetaxel (D) of patients with advanced HER2-positive BC and prior (neo)adjuvant T. METHODS: Between 06/2013 through 07/2016, 126 patients (in-label use of P at study start = full analysis se...

Descripción completa

Detalles Bibliográficos
Autores principales: Thill, Marc, Wimberger, Pauline, Grafe, Andrea, Klare, Peter, Luedtke-Heckenkamp, Kerstin, Reichert, Dietmar, Zaiss, Matthias, Ziegler-Löhr, Katja, Eckl, Tanja, Schneeweiss, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581869/
https://www.ncbi.nlm.nih.gov/pubmed/36094611
http://dx.doi.org/10.1007/s10549-022-06710-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581869/
https://www.ncbi.nlm.nih.gov/pubmed/36094611
http://dx.doi.org/10.1007/s10549-022-06710-4

Ejemplares similares